mProX™ Human GHRHR Stable Cell Line

Product Information

Target Protein

GHRHR

Target Family

Growth Hormone Releasing Hormone Receptor Family

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

CNS Research

Related Diseases

Isolated Growth Hormone Deficiency, Type Iv; Isolated Growth Hormone Deficiency, Type Ib

Gene ID

2692

UniProt ID

Q02643

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

GHRHR is a GPCR with seven hydrophobic transmembrane domains. GHRH binds to the GHRHR, which is predominately found on the pituitary somatotrope, after being released from the hypothalamus. The somatotrope becomes depolarized as a result of sodium channel opening brought on by GHRHR activation. A voltage-gated calcium channel is subsequently opened by the resulting alteration in intracellular voltage, letting calcium to enter the cell. This in turn triggers the release of prepared GH that has been stored in secretory granules. As a result of the cAMP rise, protein kinase A is stimulated, and it phosphorylates and activates the transcription factor cAMP response element binding protein, which in turn induces the manufacture of de novo GH. Mutations in the GHRHR that are autosomal recessive can cause a nearly complete lack of GH, short stature in humans, and the small phenotype in mice. The customized GHRHR stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Ernest

The cell line was exactly what I was looking for. Oct 04 2022

chat Verified Customer

chat Janice

I was so pleased with the service I received from this business. Apr 17 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Defects in the genes for growth hormone, GHRHR, and GH1 are suggested as possible causes of IGHD despite the lack of a single underlying cause.

cAMP accumulation tests, β-arrestin2 recruitment, and functional assessment of the effects of disease-causing GHRHR mutations on Gs-mediated cAMP accumulation were carried out in HEK293T cells.

Ref: Zhou, Fulai, et al. "Structural basis for activation of the growth hormone-releasing hormone receptor." Nature communications 11.1 (2020): 5205.

Pubmed: 33060564

DOI: 10.1038/s41467-020-18945-0

Research Highlights

Mutagenesis and functional studies seem to indicate that SV1 is constitutively involved in the signal bias that GHRH elicits toward β-arrestin recruitment. ERK1/2 phosphorylation and the degree of SV1 expression in prostate cancer cells are both positively connected, whereas the cAMP response is negatively correlated.
Cong, Zhaotong, et al. "Constitutive signal bias mediated by the human GHRHR splice variant 1." Proceedings of the National Academy of Sciences 118.40 (2021): e2106606118.
Pubmed: 34599099 DOI: 10.1073/pnas.2106606118

Growth hormone (GH), which is secreted by the anterior pituitary gland, is a fundamental process that affects all phases of human development and begins at conception. Growth hormone deficit (GHD), which has two types: isolated growth hormone deficiency (IGHD) and combination pituitary hormone deficiency (CPHD), is caused by variations that alter the generation, release, and functional activity of GH.
Birla, Shweta, et al. "Identification of novel GHRHR and GH1 mutations in patients with isolated growth hormone deficiency." Growth Hormone & IGF Research 29 (2016): 50-56.
Pubmed: 27114065 DOI: 10.1016/j.ghir.2016.04.001